Effects of a Single Day of Mixed Macronutrient Overfeeding on Energy Balance and Metabolic Responses
The Effects of a Single Day of Mixed Macronutrient Overfeeding on Energy Balance and Metabolic Responses in Healthy Young Men
調査の概要
詳細な説明
All testing will take place within the Carnegie Research Institute, Leeds Beckett University. We will ask all the participants to visit on five occasions for the completion of a preliminary screening trial and two single-blind counterbalanced experimental trials which each require the participants to visit the laboratory on two consecutive days. The experimental trials will be separated by a minimum of one week.
Visit 1: Preliminary Screening:
Before an individual can take part in the experiment, they will need to undergo screening. Individuals will need to complete a Health Screen Questionnaire. Individuals will be excluded from the study if they are not currently in good health, have any condition that would alter their metabolism and/or have had significant medical problems in the past that may affect the outcomes of the study. Individuals will also be asked to be complete a Three-Factor Eating Questionnaire, to check that they are not restrained eaters, and an International Physical Activity Questionnaire (IPAQ) to ensure that all participants are either sedentary or moderately active. All individuals will be asked to confirm that they have been weight stable for at least six months before participating and that they are not currently dieting. Height, body mass and age will be collected to calculate the energy requirements for the main trials based on the Mifflin equation.
Visits 2, 3, 4 and 5: Experimental Trials:
The participants will be asked to record their food intakes and activity patterns during the three days prior to the first experimental test using a food and physical activity diary. They will then be instructed to repeat this diet and activity pattern prior to the second experimental trial. Participants will be required to arrive at the laboratory for all experimental trials after an overnight fast of at least 10 hours and having refrained from any strenuous activity for 48 hours, and alcohol and caffeine consumption in the previous 24 hours. Two hours before arriving at the laboratory on the day of the experimental trials, participants will be required to ingest 300 mL of water to standardise hydration levels for the trial.
During Day One of each experimental trial, participants will consume a porridge-based breakfast, soup- and pasta-based lunch, and rice-based evening meal under laboratory observation. The meals will contain macronutrient contents representative of current dietary recommendations of 50% carbohydrate, 15% protein and 35% fat. These meals have been selected to facilitate manipulation of the energy content, while matching the meals for appearance and palatability. During one trial, these meals will provide the calculated energy requirement for each individual based on the Mifflin equation and a physical activity factor of 1.4. The meals will be covertly manipulated to provide an additional 50% energy intake during the other trial. The provision of 150% of the estimated energy requirements for participants has been used in previous research for five day periods but will only be provided for a single day in the present study. Participants will be required to consume all of the diet during the standardised phase (i.e. either their daily energy requirements or the 50% overfeed) and will be blinded to the energy content of the trials. After the consumption of the evening meal (~6pm), participants will have fulfilled the requirements for day one and will be asked not to consume any food prior to returning to the laboratory between 7am and 9am the next morning.
On Day Two of each experimental trial day, participants will arrive at the laboratory after an overnight fast and an Introcan Safety Cannula will be placed into a vein in the anticubital space for regular venous blood sampling. Blood samples will be collected in the fasted state and every 30 min after consumption of a standardised breakfast for a period of three hours. After the collection of the final blood sample, the cannula will be removed and participants will be provided with an ad libitum pasta meal (50% carbohydrate, 15% protein, 35% fat) for the assessment of energy intake. Participants will consume ad libitum meals in isolation to prevent any social influences and will be instructed to eat until 'satisfied'.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Leeds、イギリス、LS6 3QS
- Leeds Beckett University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- weight stable
- healthy
Exclusion Criteria:
- any personal history of cardiovascular or metabolic disease
- smokers
- currently dieting
- taking any medication known to influence appetite or metabolic outcomes
- highly active (IPAQ category 3)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Overfeed
Experimental trial where participants are provided with 50% higher energy intake than their estimated requirements on the first day of the trial.
|
Participants consume energy intakes that are 50% higher than their estimated requirements instead of consuming energy intakes equal to their estimated requirements
|
|
実験的:Energy Balance
Experimental trial where participants are provided with an energy intake equal to their estimated requirements on the first day of the trial.
|
Participants consume energy intakes equal to their estimated requirements instead of consuming intakes that are 50% higher than their estimated requirements
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Appetite perceptions assessed using 100mm visual analogue scales
時間枠:28 hours
|
Appetite perceptions using 100mm visual analogue scales
|
28 hours
|
|
Ad libitum energy intake
時間枠:28 hours
|
Ad libitum energy intake using an ad libitum pasta meal
|
28 hours
|
|
Plasma acylated ghrelin concentrations
時間枠:28 hours
|
Measured using ELISA from venous blood samples
|
28 hours
|
|
Plasma peptide YY concentrations
時間枠:28 hours
|
Measured using ELISA from venous blood samples
|
28 hours
|
|
Plasma GLP-1 concentrations
時間枠:28 hours
|
Measured using ELISA from venous blood samples
|
28 hours
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Palatability perceptions assessed using 100mm visual analogue scales
時間枠:28 hours
|
Palatability of the test meals assessed via 100mm visual analogue scales during the first day of each trial
|
28 hours
|
|
Blinding assessment
時間枠:One week
|
To assess whether the blinding of dietary manipulation of the first day of each trial was successful.
This will be assessed via an exit questionnaire which requires qualitative responses regarding any noticeable differences in the foods provided and what aspect of the food the participants thought had been manipulated during the trials.
|
One week
|
|
Plasma insulin concentrations
時間枠:28 hours
|
Measured using ELISA from venous blood samples
|
28 hours
|
|
Plasma glucose concentrations
時間枠:28 hours
|
Measured using photometric analysis from venous blood samples
|
28 hours
|
|
Plasma triglyceride concentrations
時間枠:28 hours
|
Measured using photometric analysis from venous blood samples
|
28 hours
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Kevin Deighton, PhD、Leeds Beckett University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 34693
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
代謝性疾患の臨床試験
-
HuidaGene Therapeutics Co., Ltd.募集
-
Hemab ApSPSI CRO募集フォン・ヴィレブランド病(VWD) | フォン・ヴィレブランド病 (VWD)、タイプ 1 | フォンウィルブランド病(VWD)、タイプ2 | Von Willebrand Disease(VWD)、タイプ3 | フォン・ウィルブランド病、タイプ2a | Von Willebrand病、タイプ2M | Von Willebrand病、タイプ2Nアメリカ, イギリス, オーストラリア
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ